Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)
16 janv. 2024 16h30 HE
|
Cellectis Inc.
NEW YORK, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Single Use Support continues to grow, expanding its team by 40%
16 janv. 2024 07h45 HE
|
Single Use Support
The forecast for innovative process solution provider Single Use Support promises growth, exemplified by the addition of 40% more staff members.
Monthly information on share capital and company voting rights
08 janv. 2024 16h30 HE
|
Cellectis Inc.
PARIS, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
First Wave BioPharma Chairman and CEO Issues Letter to Shareholders Highlighting Recent Accomplishments and Outlook for 2024
04 janv. 2024 06h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.8 Million Gross Proceeds Priced
27 déc. 2023 11h55 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Dec. 27, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (“First Wave BioPharma” or the “Company”) (NASDAQ: FWBI), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program
27 déc. 2023 06h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Dec. 27, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023
22 déc. 2023 16h30 HE
|
Cellectis Inc.
NEW YORK, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving...
Rentschler Biopharma Announces Major Client Project for New U.S. Facility at Milford, MA Site
20 déc. 2023 07h00 HE
|
Rentschler Biopharma SE
State-of-the-art Rentschler Biopharma Manufacturing Center (RBMC) facility slated to open for business next year LAUPHEIM, Germany and MILFORD, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Rentschler...
Kaplan Fox & Kilsheimer LLP Reminds Acelyrin Investors of a Class Action Lawsuit and Upcoming Deadline
17 déc. 2023 08h01 HE
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox reminds Acelyrin investors of a class action lawsuit and upcoming deadline.
EvolveImmune Therapeutics Provides Corporate and Program Update Highlighted by Closing of $37 Million Financing
13 déc. 2023 07h00 HE
|
EvolveImmune
Fundraising Includes Strategic Investment by Bristol Myers Squibb Coupled with Support from Existing Investors EvolveImmune Initiates Chemistry, Manufacturing, and Control (CMC) Activities for Lead...